ArticleOncology letters2016
Recent perspectives of breast cancer prognosis and predictive factors.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Optimizing AI-assisted decision-making in mammography screening: focusing on uncertainties.Insights into imaging · 2026Article
- The prognostic value of central excised lymph node count in N1a papillary thyroid cancer: a population-based study.Gland surgery · 2026Article
- Age-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trials.Archives of gynecology and obstetrics · 2026Article
- Correlation analysis of serum amyloid A, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index with neoadjuvant therapy efficacy and prognosis in breast cancer.Frontiers in oncology · 2026Article
- Review
- Multilevel classification framework for breast cancer cell selection and its integration with advanced disease models.iScience · 2025Review
- The Clinicopathological and Prognostic Value of CCR7 Expression in Breast Cancer Throughout the Literature: A Systematic Review and Meta-Analysis.Biomedicines · 2025Review
- Review
- Serum metabolite and metal ions profiles for breast cancer screening.Scientific reports · 2024Article
- Low progesterone receptor levels in high-grade DCIS correlate with HER2 upregulation and the presence of invasive components.Frontiers in oncology · 2024Article
- Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.Journal of cancer research and clinical oncology · 2023Article
- Estrogen Receptor Signaling in Breast Cancer.Cancers · 2023Review
- Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.Breast cancer research and treatment · 2023Article
- Clinicopathological Factors Affecting Breast Cancer Survival in Jamaican Women: A Retrospective Review.Journal of racial and ethnic health disparities · 2023Article
- Elucidating the roles of the mammary and gut microbiomes in breast cancer development.Frontiers in oncology · 2023Review
- High mitochondrial content is associated with breast cancer aggressiveness.Molecular and clinical oncology · 2021Article
- Intermammary breast cancer; the first reported case.International journal of surgery case reports · 2021Article
- Global Protease Activity Profiling Identifies HER2-Driven Proteolysis in Breast Cancer.ACS chemical biology · 2021Article
- Article
- Impact of Breast Cancer Diagnosis and Treatment on Work-Related Life and Financial Factors.Breast care (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common type of cancer affecting women worldwide. Although there have been great improvements in treating the disease and at present between 80 and 90% of the women survive ≥5-years after their primary diagnosis. However, due to the high incidence of the disease >450,000 women succumb to breast cancer annually worldwide. The majority of improvements in breast cancer survival may be explained through better knowledge of the development and progression of the disease. Consequently, the treatments employed have become more effective. Furthermore, continuous efforts are being made for the identification of novel and efficient biomarkers for the timely prognosis of breast cancer. The present review aims to examine recent perspectives of breast cancer prognosis and the predictive factors involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.